Invesco’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$164M Buy
823,604
+307,140
+59% +$60.8M 0.02% 722
2025
Q4
$97.6M Buy
516,464
+138,169
+37% +$26.5M 0.01% 840
2025
Q3
$67M Buy
378,295
+148,437
+65% +$22.1M 0.01% 975
2025
Q2
$26.1M Buy
229,858
+27,030
+13% +$2.89M ﹤0.01% 1311
2025
Q1
$21.3M Buy
202,828
+8,473
+4% +$958K ﹤0.01% 1408
2024
Q4
$20.8M Buy
194,355
+5,627
+3% +$636K ﹤0.01% 1465
2024
Q3
$18.9M Buy
188,728
+15,917
+9% +$1.6M ﹤0.01% 1487
2024
Q2
$14.6M Sell
172,811
-42,284
-20% -$3.36M ﹤0.01% 1590
2024
Q1
$15.7M Buy
215,095
+194
+0.1% +$14.3K ﹤0.01% 1567
2023
Q4
$15.3M Sell
214,901
-3,886
-2% -$229K ﹤0.01% 1558
2023
Q3
$13.1M Sell
218,787
-3,196
-1% -$210K ﹤0.01% 1585
2023
Q2
$16M Sell
221,983
-4,120
-2% -$309K ﹤0.01% 1492
2023
Q1
$16.6M Sell
226,103
-783
-0.3% -$55.7K ﹤0.01% 1446
2022
Q4
$15.2M Sell
226,886
-79,401
-26% -$5.16M ﹤0.01% 1540
2022
Q3
$16.5M Sell
306,287
-44,825
-13% -$2.64M 0.01% 1456
2022
Q2
$19.5M Buy
351,112
+39,223
+13% +$2.23M 0.01% 1389
2022
Q1
$21.9M Sell
311,889
-23,157
-7% -$1.68M 0.01% 1456
2021
Q4
$32.3M Sell
335,046
-99,962
-23% -$9.23M 0.01% 1246
2021
Q3
$37.8M Buy
435,008
+53,996
+14% +$4.18M 0.01% 1172
2021
Q2
$31.2M Buy
381,012
+59,181
+18% +$4.92M 0.01% 1333
2021
Q1
$30.6M Buy
321,831
+11,144
+4% +$1.05M 0.01% 1299
2020
Q4
$19.3M Buy
310,687
+14,802
+5% +$844K 0.01% 1450
2020
Q3
$17.6M Buy
295,885
+45,751
+18% +$3.12M 0.01% 1370
2020
Q2
$17.5M Buy
250,134
+9,210
+4% +$584K 0.01% 1339
2020
Q1
$10.9M Sell
240,924
-78,002
-24% -$4.42M ﹤0.01% 1490
2019
Q4
$20.7M Buy
318,926
+270,943
+565% +$18.1M 0.01% 1411
2019
Q3
$2.98M Sell
47,983
-540,339
-92% -$33.9M ﹤0.01% 2415
2019
Q2
$41.9M Buy
588,322
+521,413
+779% +$38.4M 0.01% 1095
2019
Q1
$5.25M Sell
66,909
-136,948
-67% -$10.4M ﹤0.01% 1976
2018
Q4
$17.3M Sell
203,857
-505,560
-71% -$53.9M 0.01% 1213
2018
Q3
$121M Buy
709,417
+235,912
+50% +$35.6M 0.04% 503
2018
Q2
$61.2M Buy
473,505
+119,335
+34% +$13.3M 0.02% 755
2018
Q1
$36.5M Buy
354,170
+16,711
+5% +$1.65M 0.01% 883
2017
Q4
$28.8M Buy
337,459
+17,590
+5% +$1.52M 0.01% 1011
2017
Q3
$27.2M Sell
319,869
-28,812
-8% -$2.28M 0.01% 1045
2017
Q2
$26.4M Sell
348,681
-222,925
-39% -$15.6M 0.01% 1066
2017
Q1
$37.7M Sell
571,606
-89,135
-13% -$5.86M 0.01% 917
2016
Q4
$41.9M Sell
660,741
-135,145
-17% -$8.53M 0.01% 870
2016
Q3
$50.7M Buy
795,886
+39,089
+5% +$2.87M 0.02% 750
2016
Q2
$56.3M Sell
756,797
-159,332
-17% -$11.8M 0.02% 705
2016
Q1
$61.2M Sell
916,129
-270,213
-23% -$16.4M 0.02% 647
2015
Q4
$80.2M Sell
1,186,342
-271,083
-19% -$16.7M 0.03% 590
2015
Q3
$77.9M Sell
1,457,425
-60,648
-4% -$3.68M 0.03% 573
2015
Q2
$95.6M Sell
1,518,073
-330,271
-18% -$18M 0.04% 531
2015
Q1
$88.9M Buy
1,848,344
+390,541
+27% +$15M 0.03% 554
2014
Q4
$48.4M Buy
1,457,803
+175,331
+14% +$5.7M 0.02% 812
2014
Q3
$37.6M Buy
1,282,472
+408,651
+47% +$13.6M 0.02% 928
2014
Q2
$34M Sell
873,821
-154,980
-15% -$6.29M 0.01% 994
2014
Q1
$43.2M Buy
1,028,801
+172,857
+20% +$7.21M 0.02% 854
2013
Q4
$28.1M Buy
855,944
+77,360
+10% +$2.52M 0.01% 1073
2013
Q3
$21M Sell
778,584
-156,813
-17% -$4.41M 0.01% 1140
2013
Q2
$21.8M Buy
+935,397
New +$16.8M 0.01% 1069

Other funds holding LGND

Invesco's LGND Position: Q1 2026 in Review

Invesco increased its Ligand Pharmaceuticals (LGND) stake by 59% in Q1 2026, buying an estimated $60.8M and bringing the position to 823,604 shares worth $164M. The position accounts for 0.02% of the portfolio, ranked #722.

Invesco first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Invesco held 823,604 shares of Ligand Pharmaceuticals worth $164M as of Q1 2026.
  • Invesco bought 307,140 Ligand Pharmaceuticals shares in Q1 2026, an estimated $60.8M.
  • Ligand Pharmaceuticals made up 0.02% of Invesco's portfolio in Q1 2026, its #722 holding.
  • Invesco first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.